MAIA Biotechnology, Inc.(MAIA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MAIA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for MAIA Biotechnology, Inc. (MAIA), a Healthcare sector company. MAIA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of MAIA by reported 13-F value include Solas Capital Management, Alyeska Investment Group, L.P., VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MAIA trades on the NYSE exchange and files with the SEC under CIK 1878313. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MAIA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MAIA Biotechnology, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-7.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+3.7% YoYOperating Income
-43.1% YoYEPS (Diluted)
+33.3% YoYTotal Assets
-4.4% YoYOp. Cash Flow
-20.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | — | — |
| Net Income | $-22.4M +3.7% | $-23.3M | — | — | — | — |
| Operating Income | $-24.3M -43.1% | $-17.0M +16.0% | $-20.2M -24.8% | $-16.2M -107.7% | $-7.8M | — |
| EPS (Diluted) | $-0.70 +33.3% | $-1.05 +29.5% | $-1.49 +14.9% | $-1.75 +26.2% | $-2.37 | — |
| Total Assets | $9.7M -4.4% | $10.2M +34.2% | $7.6M -37.1% | $12.0M +6.1% | $11.3M | — |
| Operating Cash Flow | $-18.8M -20.0% | $-15.7M -20.1% | $-13.1M -8.1% | $-12.1M -193.4% | $-4.1M | — |
Get alerted when MAIA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MAIA Biotechnology, Inc. including:
Top Institutional Holders of MAIA
Solas Capital Management, LLC
$4.4M3,030,845 shAlyeska Investment Group, L.P.
$3.6M2,500,000 shVANGUARD CAPITAL MANAGEMENT LLC
$3.5M2,413,270 sh683 Capital Management, LLC
$1.5M1,066,666 shCentric Wealth Management
$1.1M796,723 shCable Car Capital, LP
$741.0K514,583 shGEODE CAPITAL MANAGEMENT, LLC
$726.6K504,380 shBleichroeder LP
$720.0K500,000 shRENAISSANCE TECHNOLOGIES LLC
$598.6K415,700 shBlackRock, Inc.
$580.3K403,011 sh
| Fund | Value | Shares |
|---|---|---|
| Solas Capital Management, LLC | $4.4M | 3,030,845 |
| Alyeska Investment Group, L.P. | $3.6M | 2,500,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.5M | 2,413,270 |
| 683 Capital Management, LLC | $1.5M | 1,066,666 |
| Centric Wealth Management | $1.1M | 796,723 |
| Cable Car Capital, LP | $741.0K | 514,583 |
| GEODE CAPITAL MANAGEMENT, LLC | $726.6K | 504,380 |
| Bleichroeder LP | $720.0K | 500,000 |
| RENAISSANCE TECHNOLOGIES LLC | $598.6K | 415,700 |
| BlackRock, Inc. | $580.3K | 403,011 |
More Healthcare Companies
View all Healthcare →Put MAIA on your watchlist
Track score changes the day MAIA Biotechnology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MAIA a good stock to buy?
13F Pro's AI-powered analysis of MAIA Biotechnology, Inc. (MAIA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MAIA are available on the MAIA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MAIA is classified as a small company.
Which hedge funds own MAIA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MAIA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MAIA Biotechnology, Inc.'s investment landscape.